Company intelligence / Profile preview

RenThyroid

Ownership: Private
Development stage: Other

Overview

RenThyroid is an early-stage biotechnology company focused on developing novel therapies for thyroid-related disorders. The company's primary research efforts center on the development of selective thyroid hormone receptor beta (TR-beta) agonists. By targeting this specific receptor, RenThyroid aims to create treatments that provide the metabolic benefits of thyroid hormones while minimizing the adverse cardiac and bone effects typically associated with non-selective thyroid hormone replacement. Their current pipeline is focused on addressing unmet needs in hypothyroidism and potentially certain types of thyroid cancer.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RenThyroid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenThyroid.

Explore the full profile